Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

(2015) Laird Cameron et al.   DRUGS

Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system

(2014) Vivien W. Chen et al.   CANCER

310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101

(2014) D. Anderson et al.   EUROPEAN JOURNAL OF CANCER

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

(2014) Elena Ardini et al.   Molecular Oncology

Molecular Pathways: ROS1 Fusion Proteins in Cancer

(2013) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation

(2013) Ramesh Narayanan et al.   PLoS One

ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

(2012) Sai-Hong Ignatius Ou et al.   Expert Review of Anticancer Therapy

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer

(2011) T. Harada et al.   CLINICAL CANCER RESEARCH

Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma

(2011) Ting-Lei Gu et al.   PLoS One

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

(2010) Benjamin Solomon et al.   Journal of Thoracic Oncology

Trk Receptor Expression and Inhibition in Neuroblastomas

(2009) G. M. Brodeur et al.   CLINICAL CANCER RESEARCH

Rearrangements of NTRK1 gene in papillary thyroid carcinoma

(2009) A. Greco et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

TrkA overexpression enhances growth and metastasis of breast cancer cells

(2009) C Lagadec et al.   ONCOGENE

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer

(2008) Jaime Acquaviva et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER